Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


SHIP2: a "new" insulin pathway target for aging research.

Accardi G, Virruso C, Balistreri CR, Emanuele F, Licastro F, Monastero R, Porcellini E, Vasto S, Verga S, Caruso C, Candore G.

Rejuvenation Res. 2014 Apr;17(2):221-5. doi: 10.1089/rej.2013.1541.


The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain.

Soeda Y, Tsuneki H, Muranaka H, Mori N, Hosoh S, Ichihara Y, Kagawa S, Wang X, Toyooka N, Takamura Y, Uwano T, Nishijo H, Wada T, Sasaoka T.

Mol Endocrinol. 2010 Oct;24(10):1965-77. doi: 10.1210/me.2010-0163. Epub 2010 Sep 9.


Single nucleotide polymorphisms on SHIP2 is associated with Type 2 diabetes mellitus in Chinese Han population.

Hao YM, Liu QJ, Wang RY, Cao YP, Zhang Y, Zuo LF.

Eur Rev Med Pharmacol Sci. 2015 Jan;19(1):129-37.


Can Alzheimer disease be a form of type 3 diabetes?

Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G.

Rejuvenation Res. 2012 Apr;15(2):217-21. doi: 10.1089/rej.2011.1289.


Dual role of SRC homology domain 2-containing inositol phosphatase 2 in the regulation of platelet-derived growth factor and insulin-like growth factor I signaling in rat vascular smooth muscle cells.

Sasaoka T, Kikuchi K, Wada T, Sato A, Hori H, Murakami S, Fukui K, Ishihara H, Aota R, Kimura I, Kobayashi M.

Endocrinology. 2003 Sep;144(9):4204-14.


Impact of SRC homology 2-containing inositol 5'-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling.

Kagawa S, Sasaoka T, Yaguchi S, Ishihara H, Tsuneki H, Murakami S, Fukui K, Wada T, Kobayashi S, Kimura I, Kobayashi M.

J Clin Endocrinol Metab. 2005 May;90(5):2911-9. Epub 2005 Feb 1.


The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2.

Dyson JM, Kong AM, Wiradjaja F, Astle MV, Gurung R, Mitchell CA.

Int J Biochem Cell Biol. 2005 Nov;37(11):2260-5. Review.


Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.

Suwa A, Yamamoto T, Sawada A, Minoura K, Hosogai N, Tahara A, Kurama T, Shimokawa T, Aramori I.

Br J Pharmacol. 2009 Oct;158(3):879-87. doi: 10.1111/j.1476-5381.2009.00358.x. Epub 2009 Aug 19.


SHIP2: an emerging target for the treatment of type 2 diabetes mellitus.

Baumgartener JW.

Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):291-8. Review.


The lipid phosphatase SHIP2 controls insulin sensitivity.

Clément S, Krause U, Desmedt F, Tanti JF, Behrends J, Pesesse X, Sasaki T, Penninger J, Doherty M, Malaisse W, Dumont JE, Le Marchand-Brustel Y, Erneux C, Hue L, Schurmans S.

Nature. 2001 Jan 4;409(6816):92-7. Erratum in: Nature. 2004 Oct 14;431(7010):878.


The association between the SH2-containing inositol polyphosphate 5-Phosphatase 2 (SHIP2) and the adaptor protein APS has an impact on biochemical properties of both partners.

Onnockx S, De Schutter J, Blockmans M, Xie J, Jacobs C, Vanderwinden JM, Erneux C, Pirson I.

J Cell Physiol. 2008 Jan;214(1):260-72.


The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man.

Marion E, Kaisaki PJ, Pouillon V, Gueydan C, Levy JC, Bodson A, Krzentowski G, Daubresse JC, Mockel J, Behrends J, Servais G, Szpirer C, Kruys V, Gauguier D, Schurmans S.

Diabetes. 2002 Jul;51(7):2012-7.


Transcriptional profiling of C2C12 myotubes in response to SHIP2 depletion and insulin stimulation.

Huard C, Martinez RV, Ross C, Johnson JW, Zhong W, Hill AA, Kim R, Paulsen JE, Shih HH.

Genomics. 2007 Feb;89(2):270-9. Epub 2006 Nov 21.


PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes.

Tang X, Powelka AM, Soriano NA, Czech MP, Guilherme A.

J Biol Chem. 2005 Jun 10;280(23):22523-9. Epub 2005 Apr 11.


Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.

Sasaoka T, Wada T, Tsuneki H.

Pharmacol Ther. 2006 Dec;112(3):799-809. Epub 2006 Jul 13. Review.


Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome.

Kaisaki PJ, Delépine M, Woon PY, Sebag-Montefiore L, Wilder SP, Menzel S, Vionnet N, Marion E, Riveline JP, Charpentier G, Schurmans S, Levy JC, Lathrop M, Farrall M, Gauguier D.

Diabetes. 2004 Jul;53(7):1900-4.


Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity.

Wada T, Sasaoka T, Funaki M, Hori H, Murakami S, Ishiki M, Haruta T, Asano T, Ogawa W, Ishihara H, Kobayashi M.

Mol Cell Biol. 2001 Mar;21(5):1633-46.


Impact of transgenic overexpression of SH2-containing inositol 5'-phosphatase 2 on glucose metabolism and insulin signaling in mice.

Kagawa S, Soeda Y, Ishihara H, Oya T, Sasahara M, Yaguchi S, Oshita R, Wada T, Tsuneki H, Sasaoka T.

Endocrinology. 2008 Feb;149(2):642-50. Epub 2007 Nov 26.


Supplemental Content

Support Center